^
    6ms
    A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=62, Recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd.
    New P2 trial
    |
    HS-10365
    12ms
    Phase Ⅰ/Ⅱ Study of the HS-10365 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=306, Recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase classification: P1 --> P1/2 | N=48 --> 306 | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2022 --> Apr 2024
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1) • RET (Ret Proto-Oncogene)
    |
    HS-10365
    1year
    HS-10365, a highly potent and selective RET tyrosine kinase inhibitor, demonstrates robust activity in RET fusion positive NSCLC patients (AACR 2023)
    Background: Activating RET alterations drive oncogenic signaling in lung, thyroid, and other solid tumors.Until recently, only two RET tyrosine kinase inhibitor (TKI), BLU-667 and LOXO-292, had received approval for advanced NSCLC by FDA and NMPA. HS-10365 showed a manageable safety profile and favorable PK properties. The promising antitumor activity with expectable response time was observed in RET fusion+ NSCLC pts, no matter with or without previous treatments.
    Clinical
    |
    RET (Ret Proto-Oncogene) • KIF5B (Kinesin Family Member 5B) • CCDC6 (Coiled-Coil Domain Containing 6)
    |
    RET fusion • RET mutation • RET positive
    |
    Retevmo (selpercatinib) • Gavreto (pralsetinib) • HS-10365
    over2years
    Phase 1 Study of the HS-10365 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=48, Recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd.
    New P1 trial
    |
    RET (Ret Proto-Oncogene)
    |
    HS-10365